United States: Results from two uncontrolled asthma clinical trials revealed that AstraZeneca’s Breztri Aerosphere triple-combination inhaler achieved all its essential testing objectives by improving lung function measurably.
More about the news
Early trials evaluated their therapy Breztri as an approved treatment for chronic obstructive pulmonary disease patients while comparing it to dual-combination maintenance treatment.
AstraZeneca is focused on achieving USD 80 billion in revenue by 2030 following weaker results from its oncology drug performance in the recent first-quarter sales, which missed expectations.
Asthma functions as a frequent, persistent pulmonary ailment that obstructs normal respiration when lung tissues become inflamed while respiratory muscles constrict.
AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma, showing clinically meaningful improvement in lung function. https://t.co/bB2bZ87Yjn
— Reuters Legal (@ReutersLegal) May 2, 2025
The World Health Organization (WHO) reports that thousands perished while 262 million people suffered from the illness in 2019.
According to Alberto Papi, primary investigator of the studies, referring to the compounds in Breztri Aerosphere, “The results from the … trials are exciting and demonstrate the potential of budesonide/ glycopyrronium/ formoterol to evolve the standard of care to more effectively treat asthma in a single inhaled triple therapy,” Reuters reported.
AstraZeneca declared its plan to disclose comprehensive trial information to health authorities so they can evaluate Breztri for expanded approvals because the medicine generated US 978 million in sales last year while competing directly with Trelegy Ellipta from GSK.